Epeius’ Rexin-G Receives Fast Track Designation From FDA

Epeius’ Rexin-G has been granted FDA’ fast track designation, for use as a second-line treatment for advanced or metastatic pancreatic cancer.

The designation is granted following a critical evaluation of the pancreatic cancer, and the potential of Rexin-G and its progressive clinical development to address this unmet need.

Erlinda Maria Gordon, Medical Director of Epeius, said: “Rexin- G is the first in an entirely new class of targeted anti-cancer agents, with a sophistication that goes well beyond a simplistic antibody.”

“Rexin-G is the flagship of tumor-targeted genetic medicine that not only seeks out and accumulates in cancerous lesions that have spread throughout the body, but delivers a tumor-killing designer gene where it is needed most, selectively destroying tumor cells and their attendant blood supply, while sparing normal cells and healthy tissues,” she added.